A method of identifying a sulfur-treated food product, the method including: providing a sample including a food product; analyzing the sample using an analytical method to determine whether the sample includes tryptophan sulfonate; and identifying based on whether the sample includes tryptophan sulfonate that the food product is sulfur-treated, wherein the presence of tryptophan sulfonate indicates that the food product is sulfur-treated.
B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
Centre National De La Recherche Scientifique (France)
Université Paris Saclay (France)
Hong Kong Baptist University (Hong Kong)
Inventor
Wong, Ka-Leung
Goetz, Joan
Charbonniere, Loïc
Hildebrandt, Niko
Nonat, Aline
Charpentier, Cyrille
Cardoso Dos Santos, Marcelina
Cifliku, Vjona
Abstract
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula I or of formula II:
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula I or of formula II:
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula I or of formula II:
wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.
A system for adding copyright protection to implicit 3D models is provided. The system includes a first MLP module, a second MLP module, a color feature encoder, a message feature encoder, and a feature fusion module. The first MLP module outputs a geometry parameter according to a 3D coordinate parameter obtained from a 3D model source. The second MLP module outputs a base-colors parameter according to a viewing-directions parameter obtained from the 3D model source and outcomes of the first MLP module. The color feature encoder concatenates the geometry parameter, the viewing-directions parameter, and the base-colors parameter to obtain a spatial descriptor and transforms the spatial descriptor to a high-dimensional color feature field. The message feature encoder maps messages to higher dimensions so as to obtain a message feature field. The feature fusion module generates a watermarked color representation and embed the watermarked color representation into the 3D model source.
Provided herein is a resource-independent and cost-efficient antimicrobial susceptibility testing (AST) system or apparatus that can rapidly process a large number of samples. The AST system includes a barcode-like cell sensor based on an adaptive linear filter array for implementing a fully automatic and microscope-free method for counting a very small volume of cells in samples, wherein suspended cells concentrate into microbars with various lengths proportional to the number of cells. The AST system also includes an on-chip culture that takes much less time than standard methods, thereby realizing a low-cost and resource-independent platform for portable AST, from which results can be obtained through a portable device such as a cell phone.
A perovskite solar cell includes an electron-transport layer (ETL), a perovskite layer, and an HTL. The ETL is with an additive phase buried therein and disposed over a substrate with a bottom electrode. The perovskite layer is disposed above the ETL and is in contact with the ETL. The perovskite layer includes a plurality of grains which arranged on a top surface of the ETL along a direction, in which two of the adjacent grains have adjacent side surfaces to form a void there between over the top surface of the ETL. The top of the void defines a GBG side-angle with the direction, in which a mean GBG side-angle of the perovskite layer is in a range from 5 degrees to 30 degrees. A HTL is disposed over the perovskite layer and between a top electrode and the perovskite layer.
H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.
Provided herein are tuberculatin analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
8.
Methods of using metal complexes to promote wound healing
Method of inhibiting a protein-protein interaction between Von Hippel-Lindau tumor-suppressor protein and hypoxia-inducible factor 1-alpha useful in the treatment of angiogenesis-related diseases and promoting wound healing.
An herbal composition including Fructus Terminaliae Chebulae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Corydalis Yanhusuo, Herba Polygoni Chinensis, Rhizoma Atractylodis Macrocephalae, and Semen coicis Lachryrna-jobi useful for treating diseases, such as inflammatory bowel disease, by increasing regulatory T cells in a subject in need thereof, methods for preparing of use and preparation thereof.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
10.
Method and compounds for inhibiting the MCM complex and their application in cancer treatment
The Hong Kong University Of Science And Technology (China)
Hong Kong Baptist University (China)
Macau University Of Science And Technology (China)
Inventor
Liang, Chun
Jiang, Zhihong
Wang, Ziyi
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abstract
A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
The present disclosure relates to patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Provided herein are compounds useful in the treatment of inflammatory diseases, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The compounds exhibit inhibitory effects on the expression and secretion of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α.
C07D 311/62 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
13.
RIBONUCLEOPROTEINS FOR RNA THERAPEUTICS DELIVERY AND GENE SILENCING
The present invention serves as a platform technology to deliver RNA therapeutics into cells. It provides a system for delivery of RNA molecules for biomedical purposes. The modular protein-based system described in this invention allows for customization of protein modules to achieve specificity in cell-targeting, thus having the ability to be optimized for treating different diseases. Examples of types of diseases that could adopt this technology for treatment include cancer, neurodegenerative diseases and viral infection.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Porphyrin photosensitizers including 5,15-di(naphthalimide) moieties useful for photocatalytic hydrogen evolution, compositions including the same, and methods of use thereof.
The present invention provides substantia nigra organoids on silica iSECnMs and method of producing the same. The present invention also provides method of cell therapy including the substantia nigra organoids on silica iSECnMs. It also provides a method of promoting differentiation of neural stem cells to neurons includes culturing the neural stem cells on a nanostructure having a plurality of nanozigzags or nanohelices fabricated from SiO2 or TiOx.
Provided herein is a method for authenticating animal hide gelatins using peptide markers found animal hide gelatin hydrolysates. The method can be used to authenticate animal hide gelatins derived from donkey hide, horse hide, pig hide, and cattle hide.
Provided herein is a method of authenticating using peptide markers found in edible bird's nest hydrolysate. The method can be used to authenticate edible bird's nest and related products and/or distinguish between white edible bird's nest and grass edible bird's nest.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS SACLAY (France)
HONG KONG BAPTIST UNIVERSITY (Hong Kong)
Inventor
Wong, Ka-Leung
Goetz, Joan
Charbonniere, Loïc
Hildebrandt, Niko
Nonat, Aline
Charpentier, Cyrille
Cardoso Dos Santos, Marcelina
Cifliku, Vjona
Abstract
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.
The present invention relates to a system for efficient large-scale data distribution in a distributed and parallel processing environment. In particular, the present invention relates to global Top-k sparsification for low bandwidth networks. The present invention verifies that gTop-k S-SGD has nearly consistent convergence performance with S-SGD and evaluates the training efficiency of gTop-k on a cluster with 32 GPU machines which are inter-connected with 1 Gbps Ethernet. The experimental results show that the present invention achieves up to 2.7-12× higher scaling efficiency than S-SGD with dense gradients, and 1.1-1.7× improvement than the existing Top-k S-SGD.
The present invention relates to a solid-state blended polymer system that has the property of tunable lasing wavelength through adjusting the blending ratio. It can be used for health monitoring, environmental monitoring sensor and tissue imaging. Current materials do not have the broad tunable range; from blue to infra-red across the optical range. By using the same two polymers, it is possible to produce laser emitting blue to red colour. It simplifies the design, eases multi-wavelength laser sensor system integration and therefore, making the production cost-effective.
The Hong Kong University of Science and Technology (Hong Kong)
City University of Hong Kong (Hong Kong)
Inventor
Ren, Kangning
Wu, Hongkai
Wang, Zuankai
Yao, Shuhuai
Ong, Beng
Li, Wanbo
Li, Zeyu
Sun, Han
Chan, Chiu Wing
Abstract
Three-dimensional (3D) hierarchical morphologies widely exist in natural and biomimetic materials, which impart preferential functions including liquid and mass transport, energy conversion, and signal transmission for various applications. While notable progress has been made in the design and manufacturing of various hierarchical materials, the state-of-the-art approaches suffer from limited materials selection, high costs, as well as low processing throughput. Herein, by harnessing the configurable elastic crack engineering-controlled formation and configuration of cracks in elastic materials, an effect normally avoided in various industrial processes, the present invention provides a facile and powerful technique to enable the faithful transfer of arbitrary hierarchical structures with broad material compatibility and structural and functional integrity. The present invention provides a cost-effective, large-scale production method of a variety of flexible, inexpensive, and transparent 3D hierarchical and biomimetic materials.
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
The present disclosure relates to patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
This invention provides a filter-free tunable spectrum PD with a layered structure of at least two electrodes and two functional layers. Both functional layers can be a layer, a stack of inorganic semiconductors, an organic semiconductor, an organic/polymer donor/acceptor blend, a hybrid semiconductor or their combinations that has a good charge transport property. The first functional layer absorbs the shorter-wavelength EM waves and is transparent to the longer-wavelength EM waves. The second functional layer absorbs the longer-wavelength EM waves. The detection spectrum window is determined by the difference in wavelengths between the transmission cut-off wavelength of the first functional layer and absorbing edge of the second functional layer, or between the absorption edge of the first functional layer and that of the second functional layer. The present PDs can be used in imaging, thermal therapy, night-vision, Li-Fi, optical communication, environmental detection, agricultural, wellness, bioimage, food, automotive and security monitoring.
H01L 31/101 - Devices sensitive to infrared, visible or ultraviolet radiation
H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
H01L 51/44 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation - Details of devices
24.
Chromophore-labeled oligosaccharide markers and methods of use thereof
The present invention relates to methods for a blockchain search system, and particularly, the present invention relates to methods for assuring the data integrity on blockchain hybrid storage. Furthermore, the present invention provides a cost-efficient update scheme to maintain the on-chain index and authenticated data structure and is efficient and scalable under various operational parameters.
H04L 29/06 - Communication control; Communication processing characterised by a protocol
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
G06F 17/18 - Complex mathematical operations for evaluating statistical data
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
HONG KONG BAPTIST UNIVERSITY (China)
Inventor
Sheng, Ping
Dong, Zhen
Zhang, Xiaonan
Pan, Jie
Mak, Ho Yiu
Ma, Guancong
Abstract
An active sound barrier has at least one passive sound absorber at or near a boundary location. A microphone provides an output to a frequency division module, in which a plural of frequencies are filtered to provide outputs corresponding to frequency segments of the receiving transducer output at respective ones of the frequencies. An active driving circuit drives plural speakers or output transducers at respective ones of the frequencies, with at least a subset of the speakers or output transducers at or close to the barrier. The speakers or output transducers cooperate with the passive sound absorber to reduce noise across a wide frequency band as well as to effect an electrically switchable soft boundary.
G10K 11/178 - Methods or devices for protecting against, or for damping, noise or other acoustic waves in general using interference effectsMasking sound by electro-acoustically regenerating the original acoustic waves in anti-phase
H04R 1/40 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only by combining a number of identical transducers
H04R 3/12 - Circuits for transducers for distributing signals to two or more loudspeakers
G10K 11/172 - Methods or devices for protecting against, or for damping, noise or other acoustic waves in general using resonance effects
27.
Multi-mode photodetectors and methods of fabricating the same
The present invention relates to a bias-switchable spectral response high performance PD with multi-mode detection, e.g., dual-mode photoresponses in NIR and visible light ranges. The dual-mode PD has the absorber/spacer type components in its active layer, e.g., a tri-layer configuration of absorber-1 (absorber-1 absorbs the electromagnetic wave of the first wavelength comprising visible light)/optical spacer/absorber-2 (absorber-2 absorbs the electromagnetic wave of the second wavelength comprising IR light). In the presence of IR light, photocurrent generates in the IR light absorbing layer under a reverse bias. In the presence of visible light, photocurrent generates in the visible light absorbing layer under a forward bias. A bias-switchable spectral response PD offers an attractive option for applications in environmental pollution, bio, medical, agricultural, automotive, fishery, food, wellness and security monitoring, detection and imaging in two or different or multiple distinct bands.
H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
28.
TFEB activator C1 ameliorates app and tau pathology and rescues cognitive deficits in neurodegenerative diseases
The present invention relates to a method of use of a composition comprising an autophagy enhancement compound for treating neurodegenerative diseases. In particular, the said composition is used to treat the neural condition of synaptic dysfunction. Such neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, Huntington's disease, Frontotemporal dementia with parkinsonism-17 (FTDP-17), Pick disease (PiD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD) and Cerebral amyloid angiopathy.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
29.
Anti-cancer composition consisting of halofuginone and sesquiterpene lactone compounds of artemisia apiacea and use thereof
Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present disclosure relates to compounds useful in the treatment, imaging, and/or diagnosis of Epstein-Barr virus (EBV)-positive cells, such as cancer.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 7/02 - Linear peptides containing at least one abnormal peptide link
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Provided herein are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A herbal composition with significant potent therapeutic effects for treating neurodegenerative diseases by targeting both amyloid-β (Aβ) and tau-associated neurofibrillary tangles (NFTs) is provided.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
3 or a mixture thereof such that the top most layer acts as an anti-scratching layer. The multi-layered, flexible and anti-scratch metal oxides protective coating also retains the flexibility of the underlying substrate.
C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
C03C 3/06 - Glass compositions containing silica with more than 90% silica by weight, e.g. quartz
C03C 17/245 - Oxides by deposition from the vapour phase
C03C 17/36 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions at least one coating being a metal
C23C 14/30 - Vacuum evaporation by wave energy or particle radiation by electron bombardment
2 and the nanozigzags having a pitch of 80 nm to 250 nm, and a contact depth of 90 nm to 260 nm. A method of cell therapy including substantia nigra organoids formed on silica iSECnMs is also provided.
The present disclosure provides peptides useful as inhibitors of the dimerization interface of EBNA1. The present disclosure also provides methods for treating and imaging EBV-associated cancers.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to 3D mask face anti-spoofing with remote photoplethysmography. More particularly, it relates to a local rPPG correlation model to extract discriminative and robust local rPPG signal patterns so that an imposter can better be detected regardless of the material and quality of the mask.
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
C07C 69/34 - Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
C07C 69/736 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 9/00 - Medicinal preparations characterised by special physical form
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
C07C 69/30 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
C07C 69/616 - Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety polycyclic
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 69/74 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
C07C 69/92 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
38.
Identification of cyclic peptide agonists of galanin receptor 2 and 3 guided by spexin solution structure
Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (Hong Kong)
Inventor
Ren, Kangning
Ma, Dik-Lung
Hu, Chong
Li, Wanbo
Lin, Sheng
Wu, Hongkai
Abstract
A method for fabricating flexible microfluidic chips with plastic membranes. In particular, the present invention provides a single-step method for microchannel fabrication of microfluidic chips in a fast and cost-efficient manner.
B29L 31/50 - Footwear, e.g. shoes or parts thereof
B29K 75/00 - Use of polyureas or polyurethanes as moulding material
B29C 49/00 - Blow-moulding, i.e. blowing a preform or parison to a desired shape within a mouldApparatus therefor
B29C 65/70 - Joining of preformed partsApparatus therefor by moulding
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
A61K 8/33 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 69/34 - Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
C07C 69/736 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
A method to coat oxide-based color pigments with an ultrasound-assisted coating of nanofiber or other nanostructures in order to enhance heat-fastness and color performance to said color pigments is presented. In particular, the present invention provides a method to coat oxide-based color pigments with nano-coating materials, including but not limited to, alumina and/or silica at different dosage levels, with nanospike, nanoneedle, nanoplate, and/or nanoflower morphology towards enhancing the heat-fastness and color performance of said color pigments.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
43.
Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatment of tumorous pathologies
The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol or its derivatives/chemical variants in the manufacture of a medicament for the treatment of tumors or cancers. The dihydrostilbenes can be used in the treatment or delay of progression of a cancer in a patient or used in a pharmaceutical formulation for the aforementioned purposes.
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
44.
Biometric authentication based on gait pattern or writing motion with an inertial measurement unit
The present invention relates to use an Inertial Measurement Unit (IMU) to record the acceleration trajectory of a person's gait or pen-less handwriting motion or any predesignated gestures, and to convert the data to a unique biometric pattern. The pattern is unique for each case and can be used as biometric security authentication.
The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
C07D 319/08 - 1,3-DioxanesHydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin αvβ3.
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present disclosure relates to miliusane and analogs thereof that are useful as anti-virals, such as anti-HIV and anti-influenza virus agents. The present disclosure provides methods for treating viral infections, such as AIDS, HIV, and influenza infections.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
C07D 307/94 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
48.
Enhancing thermal stability of bulk heterojunction solar cells with fluorenone derivatives
The present invention relates to the provision of an organic compound or compounds containing a fluorenone derivative structure or its substituted derivatives to enhance the thermal stability of organic solar cells.
C07C 13/567 - FluorenesCompletely or partially hydrogenated fluorenes
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
C07C 255/41 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
49.
Iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent
Kaohsiung Medical University (Taiwan, Province of China)
Inventor
Leung, Chung-Hang
Zhong, Hai-Jing
Ma, Dik-Lung
Wang, Hui-Min
Abstract
Bromodomain-containing protein 4 (BRI)) has recently emerged as an attractive epigenetic target for anticancer therapy. Iridium(III) complexes are useful as irreversible inhibitor of BRD4. Complex 1a of the formula:
is particularly useful.
The present invention provides nanostructures for use in proliferation and differentiation of neural stem cells. The present invention also provides method of proliferating and differentiating neural stem cells.
4 is an amino acid sequence comprising CAhxYFMVFGGRrRK and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of EBNA1, a critical process for the growth of EBVs and the associated tumors. The present invention also provides method of treating and imaging EBV-associated cancers.
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
A61K 36/14 - Cupressaceae (Cypress family), e.g. juniper or cypress
A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
52.
Method of use of diterpenoid derivatives as anticancer agents
The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
C07D 319/08 - 1,3-DioxanesHydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs). One embodiment of the present invention also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment of the present invention also has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer miliusane lactam compounds. The present invention also includes its preparation and application method for treating cancer.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
B01J 20/281 - Sorbents specially adapted for preparative, analytical or investigative chromatography
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
56.
Solution process for fabricating high-performance organic thin-film transistors
The present invention relates to a solution or ink composition for fabricating high-performance thin-film transistors. The solution or ink comprises an organic semiconductor and a mediating polymer such as polyacrylonitrile, polystyrene, or the like or mixture thereof, in an organic solvent such as chlorobenzene or dichlorobenzene. The percentage ratio by weight of semiconductor:mediating polymer ranges from 5:95 to 95:5, and preferably from 20:80 to 80:20. The solution or ink is used to fabricate via solution coating or printing a semiconductor film, followed by drying and thermal annealing if necessary to provide a channel semiconductor for organic thin-film transistors (OTFTs). The resulting OTFT device with said channel semiconductor has afforded OTFT performance, particularly field-effect mobility and current on/off ratio that are superior to those OTFTs with channel semiconductors fabricated without a mediating polymer.
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
C09D 11/106 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
C09D 11/107 - Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds from unsaturated acids or derivatives thereof
H01L 51/05 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for rectifying, amplifying, oscillating or switching and having at least one potential-jump barrier or surface barrier; Capacitors or resistors with at least one potential-jump barrier or surface barrier
B32B 3/10 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material
C09D 11/12 - Printing inks based on waxes or bitumen
C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
C09D 127/06 - Homopolymers or copolymers of vinyl chloride
C09D 133/12 - Homopolymers or copolymers of methyl methacrylate
C09D 165/00 - Coating compositions based on macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCoating compositions based on derivatives of such polymers
C09D 133/20 - Homopolymers or copolymers of acrylonitrile
This invention relates to a tunable amplified spontaneous emission (ASE) laser source comprising at least two laser sources excited by a single pump laser. More particularly, the present invention relates to a tunable amplified spontaneous emission (ASE) laser source comprising at least two laser sources excited by a single pump laser wherein said at least two laser sources each comprise an organic laser or a cascaded organic laser. The invention is used for providing a tunable amplified spontaneous emission (ASE) laser source comprising at least two laser sources excited by a single pump laser.
Maytenus variabilis (Loes.) C. Y. Cheng (Celastraceae). The invention also includes its preparation and application method for treating cancer and obesity diseases.
C07K 7/64 - Cyclic peptides containing only normal peptide links
C07C 229/04 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof cyclic, e.g. valinomycins
60.
Magnetic platform for direct and multiplex immune-based detection of trace amount of protein biomarkers
The present invention discloses a magnetic platform for direct and multiplex immune-based detection of trace amount of protein biomarkers for cancers, neurodegenerative disease such as Alzheimer's disease
The present invention relates to a nano bi-material, electromagnetic spectrum shifter based on said nano bi-material and method to produce said electromagnetic spectrum shifter using said nano bi-material. In particular, the present invention provides nano bi-material based electromagnetic spectrum shifter, e.g. color filters, with a wide range of transmission and color tunability and methods to produce said color filters. The present invention has applications in color filtration and production of color filters; reflector and production of reflectors; and electromagnetic spectrum shifter and production of electromagnetic spectrum shifters.
G02B 1/14 - Protective coatings, e.g. hard coatings
C03C 17/09 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with metals by deposition from the vapour phase
C23C 14/18 - Metallic material, boron or silicon on other inorganic substrates
C23C 14/20 - Metallic material, boron or silicon on organic substrates
C03C 17/00 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating
C03C 17/36 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions at least one coating being a metal
C03C 17/38 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions at least one coating being a metal at least one coating being a coating of an organic material
62.
Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
A polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, is disclosed as a remedial agent. In particular, the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs) is presented. One embodiment also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
Dendrobium-derived extracts or ingredients or stilbenoids is shown in the formulation of skin-protection, skin-whitening and/or anti-skin aging products.
C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 69/34 - Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
A61K 8/33 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
C07C 69/736 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 69/753 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
64.
Algorithms for gait measurement with 3-axes accelerometer/gyro in mobile devices
The present invention relates to a method of gait measurement using tri-axial accelerometer/gyro in mobile devices. In particular, the present invention relates to algorithms for gait measurement using tri-axial accelerometer/gyro in mobile devices for monitoring and improving the physical movement of a moving subject.
Lasia spinosa Linn. Thwait or chemically synthesized and its specific anticancer/antitumor activity. This invention has a specific application in treating human esophageal cancer.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
66.
Method and apparatus for assuring location data integrity with minimum location disclosure
An invention relates to method and apparatus of a location assurance system and particularly, although not exclusively, the present invention also relates to method and apparatus for assuring location data integrity with minimum location disclosure. The present invention also relates to method and apparatus for assuring location data integrity with minimum location disclosure with protocols to authenticate both spatial and spatio-temporal predicates.
G06F 21/00 - Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
H04L 9/36 - Arrangements for secret or secure communicationsNetwork security protocols with means for detecting characters not meant for transmission
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
H04L 29/06 - Communication control; Communication processing characterised by a protocol
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 36/888 - Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
68.
Method of using dihydro-resveratrol for treating acute pancreatitis and associated pulmonary injury
The present invention relates to a method of using trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol for treating acute pancreatitis in a subject in needs thereof. More particularly, the present invention relates to a method of using dihydro-resveratrol, its derivatives and/or chemical variants as a remedial agent. The present invention particularly relates to the amelioration of tissue injury for the management of acute pancreatitis associated pulmonary injury of a subject.
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
C07C 39/15 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
69.
Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities
This invention relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds. More particularly, it relates to the quick and efficient synthesis of anti-tumor or anti-cancer compounds comprising phenylacetophenone derivatives using oxabenzonorbornadienes with terminal alkynes.
C07D 319/22 - 1,4-DioxanesHydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
C07D 317/70 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
70.
Triptolide derivatives and preparation method and use thereof
7, G, A, B, M, Z and X are described. The present invention uses a nucleic acid aptamer and triptolide or modified compounds thereof as the starting materials, and introduces a linking group A at the C-14 hydroxyl group, epoxy groups and five-membered ring lactones in triptolide, then connects it to a nucleic acid aptamer B, and obtains the triptolide-nucleic acid aptamer derivatives. The triptolide-nucleic acid aptamer derivatives of the present invention have the characteristics of good targeting, a high anti-cancer activity, low toxicity and side effects, good water solubility and high bioavailability, and the preparation method of the present invention is scientific and reasonable and has a controllable quality and good repeatability, and is thereby suitable for production.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
C07J 73/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
71.
Method for antagonizing STAT3 dimerization and compounds for use therein
Kaohsiung Medical University (Taiwan, Province of China)
Inventor
Leung, Chung-Hang
Ma, Dik-Lung
Wang, Hui-Min
Abstract
A compound of the formula:
Also, a method for antagonizing STAT3 dimerization in a patient in need thereof which by administering to such patient a therapeutically acceptable dose of the compound of Formula I. Further, a method for treating a cancer patient in need thereof by administering a therapeutically effective dose of the compound of Formula I.
An assembly for a ball and socket joint forming a universal joint is disclosed as including a socket joint assembly comprising a first dual-ended sphere-receiving element and a second dual-ended sphere-receiving element joined together by a flush fitting joint.
F16C 11/06 - Ball-jointsOther joints having more than one degree of angular freedom, i.e. universal joints
F16M 11/14 - Means for attachment of apparatusMeans allowing adjustment of the apparatus relatively to the stand allowing pivoting in more than one direction with ball-joint
F16M 11/20 - Undercarriages with or without wheels
F16M 11/40 - Undercarriages with or without wheels changeable in height or length of legs, also for transport only by means of coilable or bendable legs
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention is in the field of pharmaceuticals and chemical industries. In particular, one aspect of the present invention relates to methods for labeling, imaging and detecting the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro and in vivo via magnetic resonance and florescence imaging by using modified carbazole-based fluorophores. A further aspect of the present invention relates to a method of reducing and preventing aggregation of beta-amyloid peptides for Alzheimer's disease (AD) as well as of treating and/or preventing Alzheimer's disease by using the modified carbazole-based fluorophore. The modified carbazole-based fluorophore according to an embodiment of the present invention is prepared by conjugating a carbazole-based fluorophore with magnetic nanoparticles to form a conjugate which is permeable to blood brain barrier of a subject being introduced therewith.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
75.
MTOR-independent activator of TFEB for autophagy enhancement and uses thereof
The present invention relates to a composition comprising an autophagy enhancement compound. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.
The present invention discloses a composite biogenic flocculant for enhancing flocculation and dewaterability of chemically enhanced primary treatment (CEPT) sludge. The present invention also discloses method of conditioning CEPT sludge using the composite biogenic flocculant.
The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional—PDT and imaging—gadolinium complex (Gd—N) with a molecular formula of:
which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species—singlet oxygen—prior to due excitation. The present invention also provides the use of Gd—N as a tumor selective PDT photosensitizer modality.
The present invention provides a slow and controlled released liposomal gel composition for subcutaneous administration comprises insulin or exenatide as active ingredient for reduction of blood sugar level and method of preparation thereof. Said controlled released composition has high bioavailability and is demonstrated to be able to sustain release therapeutically effective concentration of drug over a period of time and without rapid release of drug after initial administration. Method of preparing the controlled released composition of the present invention comprises the following steps: mixing insulin or exenatide, lipid and aqueous dispersion medium together; then mixing with poloxamer (e.g. F127 or P123) and/or gelatin and hyaluronic acid (HA) or the like gel solution so as to form a protective layer on surface of every lipid micro vesicles or nano-vesicles for use in intramuscular, abdominal and subcutaneous administration. A single administration of the present composition lasts 2 to 7 days to reduce side-effects, such as pain and irritation.
The invention relates to method and apparatus of an eye gaze tracking system. In particular, the present invention relates to method and apparatus of an eye gaze tracking system using a generic camera under normal environment, featuring low cost and simple operation. The present invention also relates to method and apparatus of an accurate eye gaze tracking system that can tolerate large illumination changes.
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer agents based on miliusane compounds. The present invention also includes its preparation and application method for treating cancer.
C07D 307/94 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
82.
Synthesis of autophagy inducing compound and the uses thereof
The present invention relates to a composition comprising compound of formula CB6 or CB8,
the pharmaceutically-acceptable carrier, solvent, the salts thereof or a combination thereof which is used to treat autophagy-associated diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. The present invention also relates to a method of treating these diseases by administering a therapeutically-effective amount of the compound to the subject in need of the treatment. The present invention further relates to the use of this compound in preparation of the composition to treat the diseases.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
83.
BioFerric-flocculant enhanced primary treatment process (BEPT) for sewage treatment
The present invention relates to one step “BioFerric flocculant enhanced primary treatment” (BEPT) process for domestic sewage treatment. More particularly, it relates to a novel composite flocculant consisting of acidophilic bacteria, and bacteriogenic flocculants for sewage flocculation and settling that enhanced the sewage treatment process by minimizing the chemical uses and steps and direct dewatering of sludge without preconditioning.
Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
A real-time method to monitor and harvest stem cells is provided in the present invention. In particular, the present invention provides a real-time method to monitor and harvest neural stem cells. The present invention has applications in providing an individualized cell replacement therapy for patient in need thereof. More specifically, the present invention has applications in performing real-time monitoring and harvesting of neural stem cells using magnetic resonance imaging (MRI).
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
This invention provides a non-invasive method for diagnosing performance of a vehicle. The method comprises using a 3-axis accelerometer to perform diagnosis of the performance of an internal combustion engine, the performance of the engine including an engine power loss and one or more flaws associated with the engine mount. The method is also usable for diagnosing deterioration of a suspension system of said vehicle. An apparatus comprising a 3-axis accelerometer for diagnosing performance of a vehicle is also provided. In one embodiment, the 3-axis accelerometer is embedded in a smart phone.
This invention provides a system and a method for measuring displacements and movements, particularly for measuring very fine displacements and very minute movements. Position, vibration and rotational/angular movements can be measured. One or more directions can be measured simultaneously. In one embodiment, the system comprises one or more measuring means at least configured to tune multiple color emissions from a laser comprising an organic laser and/or a cascaded organic laser, such that the tuned multiple color emissions of the laser are used in measurements. The system is scalable in order to support measurement across a very large space. Optionally, the system further comprises a thin film laser generating device for generating said laser, blue and green emission organic semiconductors for generating said organic laser, and laser sensors for sensing said laser where said laser sensors comprise organic laser sensors and/or cascaded organic laser sensors.
The present invention relates to a composition comprising an autophagy enhancement compound. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.
The present invention discloses a composite biogenic flocculant for enhancing flocculation and dewaterability of chemically enhanced primary treatment (CEPT) sludge. The present invention also discloses method of conditioning CEPT sludge using the composite biogenic flocculant.
The present invention relates to a method of gait measurement using tri-axial accelerometer/gyro in mobile devices. In particular, the present invention relates to a method of gait measurement using tri-axial accelerometer/gyro in mobile devices for monitoring and improving the physical movement of a moving subject.
The present invention provides composition and method for inducing melanogenesis. The composition comprising an effective amount of saponins extracted from herbal plants.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Radix Astragali, Radix Codonopsis, Ganoderma sinense, or mixtures thereof, and their extraction process. The present invention further relates to a method of modulating immune system by applying said pharmaceutical composition to a subject suffering from cancers, and a method of preventing and/or pretreating and/or treating cancers in the subject, where said method comprises applying said pharmaceutical composition before/during chemotherapy.
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
93.
Chinese medicinal formulation for treating inflammatory bowel disease and the preparation thereof
This invention relates to a Chinese medicinal formulation for the treatment of inflammatory bowel diseases, and a method of preparation thereof. The formulation comprises herbal components selected from a group consisting of Radix Codonopsis (Dangshen), Rhizoma Atractylodis Macrocephalae (Bai Zhu), Sclerotium Poriae Cocos (Fu Ling), Rhizoma Zingiberis Officinalis (Gan Jiang), Radix Paeoniae Alba (Bai Shao) and Rhizoma Coptidis (Huanglian).
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound of formula (I):
Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
C07C 33/38 - Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
C07C 35/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed ring system having two rings
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
96.
Quality control marker and its use in herbs authentication
This invention is in the field of pharmaceuticals, health supplements and chemical industries. In particular, this invention relates a herbal composition that compensates the Aβ increasing effects of existing treatment, and on the regulatory processing of amyloid-β protein precursor (APP), therefore presenting a significantly more potent treatment for neurodegenerative diseases that does not associate with any β-amyloid increasing effect.
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
98.
Use of a flavanol glycoside for suppressing activation of stellate cells
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Poria for skin care. It further relates to a method for preparing bioactive fraction of this formula and to the applications of the bioactive fraction in skin-whitening and anti-skin-aging.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to methods for labeling, imaging and detecting the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro by using carbazole-based fluorophores. A further aspect of the present invention relates to a method of reducing and preventing aggregation of beta-amyloid peptides for Alzheimer's disease (AD) as well as of treating and/or preventing Alzheimer's disease by using carbazole-based fluorophores.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
patents